No Data
No Data
NeuroBo Pharmaceuticals Stock Slides Despite Animal Study Showing Wegvoy, Liver Fibrosis Success
NeuroBo Pharmaceuticals Inc (NASDAQ:NRBO) shares were down more than 6% at last check Wednesday.The Boston-based company announced preclinical data for its novel "G-Protein-Coupled Receptor 119 (GPR11
NeuroBo Says DA-1241, Wegovy Combo Shows Potential in Treating MASH
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersMustang Bio (NASDAQ:MBIO) stock increased by 51.6% to $0.47 during Wednesday's pre-market session. The market value of their outstanding shares is at $5.8 million. NeuroBo Pharmaceuticals (NASD
Express News | NeuroBo Pharmaceuticals Sees Reporting Top-Line Data From Both Parts of Ongoing Phase 2a Clinical Trial in Mash in Q4 of This Year
Express News | NeuroBo Pharmaceuticals' Da-1241 in Combination With Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical Mash Models Compared to Either Treatment, Alone
NeuroBo Pharmaceuticals' DA-1241 in Combination With Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone
"The data being presented at EASL further strengthen the pre-clinical evidence that DA-1241's activation of GPR119 has therapeutic potential for the reduction of hepatic steatosis, inflammation, fibrosis, and improved glucose control," stated Hyung Heon Kim, President and Chief Executive Officer of NeuroBo. "
No Data